Elizabeth Holmes and Ramesh Sunny Balwani founded Theranos, a biotechnology company that claimed to revolutionize medical testing by running accurate blood tests on tiny samples drawn from a finger prick. In reality, the technology failed to work as advertised, and the defendants misled investors, partners, and patients about the device's capabilities, financial health, and partnerships. After a two-and-a-half-year investigation, a grand jury indicted them for conspiracy and wire fraud. Following separate trials, Holmes was convicted on four counts of investor fraud, while Balwani was convicted on all counts, including patient fraud. Both were sentenced to prison terms and ordered to pay $452 million in restitution. They appealed, challenging the admissibility of various pieces of evidence, including testimony from former employees, a CMS inspection report, and evidence regarding the voiding of test results, as well as the calculation of their restitution.
The panel addressed several evidentiary and legal challenges. First, regarding Federal Rule of Evidence 702, the court clarified that there is no 'on-the-job' exception; if a witness offers an opinion based on specialized knowledge, training, or education, it constitutes expert testimony regardless of their title as a lay witness. The court found that testimony from Dr. Kingshuk Das, Dr. Adam Rosendorff, and Dr. Mark Pandori regarding the reliability of the Edison device and quality control issues veered into expert territory because it required specialized scientific analysis. However, the court ruled this error was harmless because the witnesses would have qualified as experts, their testimony was cumulative of other evidence, and the evidence against the defendants was overwhelming. Conversely, testimony from Erika Cheung regarding quality control failures was properly admitted as lay opinion because it was based on her direct perception of the device's operation, not specialized knowledge. Second, the court upheld the admission of the CMS report, finding it relevant to prove Holmes's knowledge and intent regarding the lab's condition and that its probative value was not substantially outweighed by prejudice, especially given jury instructions. Third, the court rejected the argument that voiding test results was a 'subsequent remedial measure' under Rule 407, finding the decision was not voluntary but rather a response to regulatory findings. Fourth, the court affirmed the district court's limitation on cross-examination of a witness regarding his post-Theranos employment, noting the Confrontation Clause does not require unlimited questioning on collateral matters. Fifth, the court rejected the claim that the indictment was constructively amended, holding that the indictment gave fair notice that the fraud involved misrepresentations about the accuracy of tests regardless of the device used. Finally, regarding restitution, the court agreed that the district court should have considered the residual value of the shares but found the error harmless because the victims were unable to liquidate the shares, meaning their actual loss equaled their total investment.
The decision solidifies the standard that lay witnesses cannot bypass Rule 702 requirements by claiming on-the-job experience when offering opinions requiring specialized knowledge. It confirms that evidentiary errors regarding expert testimony may be deemed harmless if the witness would have qualified as an expert and the evidence is cumulative. The ruling also clarifies that restitution under the Mandatory Victims Restitution Act is based on the property lost (the investment) rather than economic loss, but requires courts to account for any residual value of returned property to avoid double recovery, though this did not alter the outcome here due to the victims' inability to sell the shares.